Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer vaccine train the body to fight advanced tumors?

NCT ID NCT04864418

Completed ⭐️ CURE ⭐️ Sponsor: Aston Sci. Inc. Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participants receive a series of injections at different dose levels to find the best and safest dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a therapeutic cancer vaccine called AST-021p
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early phase 1 trial with only 22 participants, focused on safety and dosing. It is too soon to know if the vaccine will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

  • Korea University Anam Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Seoul ST. Mary's Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.